Canopy Growth reported net revenue growth of 22% in its second quarter fiscal 2027 results, driven primarily by a 141% increase in international cannabis markets as the Canadian producer expands its global footprint.
The company's cannabis segment grew 30% overall, with Canadian operations showing solid gains across both medical and adult-use channels. Medical cannabis revenue in Canada rose 18%, while adult-use sales climbed 17% compared to the same quarter last year.
The international surge reflects Canopy's strategic pivot toward European and other overseas markets, where medical cannabis frameworks have matured faster than many observers anticipated. Research from the European Monitoring Centre for Drugs and Drug Addiction shows prescription cannabis programs now operate in over 20 European countries, creating new revenue opportunities for established producers.
The EU Supply Chain Play
Canopy strengthened its end-to-end EU Good Manufacturing Practice (GMP) supply chain during the quarter, positioning itself to serve growing demand in European medical markets. GMP certification is mandatory for cannabis products sold as pharmaceuticals in the European Union, creating a significant barrier to entry for producers without certified facilities.
The company operates GMP-certified cultivation and processing facilities in multiple countries, allowing it to supply European markets directly rather than exporting from Canada. This vertical integration reduces shipping costs and regulatory complexity while improving margins on international sales.
European medical cannabis markets remain smaller than North American adult-use markets but offer higher per-gram prices and more stable regulatory environments. Germany alone imported over 30,000 kilograms of medical cannabis in 2024, according to federal health ministry data, and that figure has grown substantially since partial legalization of adult-use possession in April 2024.
Domestic Growth Continues
While international markets grabbed headlines, Canopy's Canadian business showed steady improvement. The 18% medical revenue increase suggests the company is retaining market share in a segment that has faced pressure from adult-use substitution. Medical patients in Canada can access higher THC limits and claim tax deductions, but many have migrated to cheaper adult-use products.
The 17% adult-use growth outpaced overall Canadian market expansion, which Statistics Canada pegged at roughly 8% year-over-year in recent quarters. That indicates Canopy is gaining share in a competitive market dominated by value brands and provincial retailers.
Canopy has restructured significantly over the past three years, closing cultivation facilities, cutting staff, and focusing on profitable product lines. The company operates fewer cultivation square feet than at its peak but generates higher revenue per square foot through improved efficiency and product mix.
What's Next
The international expansion strategy faces execution risks. European medical markets remain fragmented, with each country maintaining distinct regulatory requirements and reimbursement structures. Building distribution networks and securing pharmacy partnerships requires sustained investment with uncertain timelines to profitability.
But the 141% international growth rate suggests Canopy's early investments are paying off. The company declined to provide specific country-by-country revenue breakdowns, making it difficult to assess which markets are driving growth and which remain underdeveloped.
Canopy's next earnings report will show whether the international momentum continues and whether Canadian operations can maintain their growth trajectory amid ongoing price compression and market saturation. The company has not announced the date for its third quarter fiscal 2027 results.
This article is based on original reporting by www.cannabisbusinesstimes.com.
